ALDA Pharmaceuticals Corp.: T36(R) Antiseptic Hand Sanitizer Kills "Superbugs" in 15 Seconds
02 Dicembre 2010 - 3:00PM
Marketwired
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the
"Company") announces that new tests have shown that T36® Antiseptic
Hand Sanitizer is completely effective against two types of new
"superbugs" within 15 seconds. The testing was conducted at
BioScience Laboratories in Bozeman, MT against antibiotic-resistant
strains of E. coli and Klebsiella. These strains have taken genes
from other bacteria that have developed the ability to digest
nearly all antibiotics, including penicillin-like antibiotics that
possess broad spectrum antibacterial properties and are typically
used as a last resort. Such genetic "swapping" is common among
bacteria and is a major cause of antibiotic resistance.
Dr. Terrance Owen, President & CEO comments, "T36®
Antiseptic Hand Sanitizer works in a completely different way than
antibiotics. It kills infectious organisms by disrupting their cell
walls so the presence of antibiotic-digesting enzymes does not stop
it from working. Since these infections are so dangerous, it is
important to prevent them from happening in the first place. Proper
hygiene, including the use the of hand sanitizers and disinfectants
such as T36® Antiseptic Hand Sanitizer and T36® Disinfectant, is a
very important step in preventing the spread of potentially
incurable diseases."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control
therapeutics derived from its patented T36® technology. The Company
trades on the TSX Venture Exchange under the symbol APH and on the
OTCQB under the symbol APCSF. The Company was the Official Supplier
to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010
Paralympic Winter Games and is the Official Supplier to the
Canadian Olympic Committee, the 2010 Canadian Olympic Team and the
2012 Canadian Olympic Team for antiseptic hand sanitizer,
disinfectant and disinfectant cleaning products. The Company was
also selected as one of the TSX Venture 50 companies in the
Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
www.aldacorp.com
The Units, common shares, warrants and the common shares
issuable upon exercise of the warrants have not been registered
under the United States Securities Act of 1933 (the "Act") and may
not be offered or sold absent registration under the Act or an
applicable exemption from the registration requirements thereof.
This news release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction or
an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements:
Information in this press release that involves ALDA's
expectations, plans, intentions or strategies regarding the future
are forward-looking statements that are not facts and involve a
number of risks and uncertainties. ALDA generally uses words such
as "outlook", "will", "could", "would", "might", "remains", "to
be", "plans", "believes", "may", "expects", "intends",
"anticipates", "estimate", "future", "plan", "positioned",
"potential", "project", "remain", "scheduled", "set to", "subject
to", "upcoming", and similar expressions to help identify
forward-looking statements. The forward-looking statements in this
release are based upon information available to ALDA as of the date
of this release, and ALDA assumes no obligation to update any such
forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These
statements are not guarantees of the future performance of ALDA and
are subject to risks, uncertainties and other factors, some of
which are beyond its control and may cause actual results to differ
materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor
Relations 604-377-5781 or 604-521-8300 Ext 203 604-521-8322 (FAX)
scott_young@aldacorp.com www.aldacorp.com
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Set 2023 a Set 2024